Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Get Free Report) traded up 0.2% on Thursday . The stock traded as high as $84.66 and last traded at $84.64. Approximately 4,804 shares were traded during trading, a decline of 27% from the average daily volume of 6,590 shares. The stock had previously closed at $84.44.
Invesco Biotechnology & Genome ETF Stock Performance
The stock has a market capitalization of $263.23 million, a PE ratio of 20.44 and a beta of 0.72. The business’s 50-day moving average is $81.96 and its two-hundred day moving average is $81.33.
Institutional Trading of Invesco Biotechnology & Genome ETF
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Invesco Biotechnology & Genome ETF by 9,169.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after acquiring an additional 339,271 shares during the period. United Capital Financial Advisors LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $5,946,000. Q3 Asset Management acquired a new position in Invesco Biotechnology & Genome ETF during the 4th quarter worth approximately $1,431,000. Royal Bank of Canada increased its position in Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares during the period. Finally, LPL Financial LLC increased its position in Invesco Biotechnology & Genome ETF by 5.0% during the 4th quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock worth $7,994,000 after purchasing an additional 4,617 shares during the period.
Invesco Biotechnology & Genome ETF Company Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Featured Articles
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}